AG˹ٷ

STOCK TITAN

[8-K] FTAI Infrastructure Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Form 4 highlights: Journey Medical Corp. (DERM) reported that director Jayne Miranda Toledano received 20,000 restricted stock units (RSUs) on 05-Aug-2025 at $0 cost under the 2015 Stock Plan. The award lifts her total beneficial ownership to 108,618 common shares.

The RSUs vest in three tranches: 6,667 shares on 05-Aug-2028, 6,667 on 05-Aug-2029 and 6,666 on 05-Aug-2030. No sales, option exercises or other dispositions were disclosed.

  • The grant is a non-cash equity incentive intended to align the director’s interests with long-term shareholder value.
  • Any share dilution will be incremental and spread over the 2028-2030 period, contingent on continued service and vesting conditions.

Punti salienti del Modulo 4: Journey Medical Corp. (DERM) ha comunicato che la direttrice Jayne Miranda Toledano ha ricevuto 20.000 unità di azioni vincolate (RSU) il 05-ago-2025 senza alcun costo, nell'ambito del Piano Azionario 2015. Questo premio porta la sua proprietà totale a 108.618 azioni ordinarie.

Le RSU maturano in tre tranche: 6.667 azioni il 05-ago-2028, 6.667 il 05-ago-2029 e 6.666 il 05-ago-2030. Non sono state segnalate vendite, esercizi di opzioni o altre disposizioni.

  • Il premio è un incentivo azionario non monetario volto ad allineare gli interessi della direttrice con il valore a lungo termine per gli azionisti.
  • Eventuali diluizioni azionarie saranno incrementali e distribuite nel periodo 2028-2030, soggette a condizioni di servizio continuativo e maturazione.

Aspectos destacados del Formulario 4: Journey Medical Corp. (DERM) informó que la directora Jayne Miranda Toledano recibió 20,000 unidades de acciones restringidas (RSU) el 05-ago-2025 sin costo alguno bajo el Plan de Acciones de 2015. Esta concesión eleva su propiedad total a 108,618 acciones comunes.

Las RSU se liberan en tres partes: 6,667 acciones el 05-ago-2028, 6,667 el 05-ago-2029 y 6,666 el 05-ago-2030. No se informaron ventas, ejercicios de opciones ni otras disposiciones.

  • La concesión es un incentivo de capital no monetario diseñado para alinear los intereses de la directora con el valor a largo plazo para los accionistas.
  • Cualquier dilución de acciones será incremental y se distribuirá durante el período 2028-2030, condicionada al servicio continuo y a las condiciones de adquisición.

Form 4 주요 내용: Journey Medical Corp. (DERM)은 이사 Jayne Miranda Toledano가 2015� 주식 계획� 따라 2025� 8� 5일에 무상으로 20,000 제한 주식 단위(RSU)� 받았다고 보고했습니다. � 수상으로 그녀� � 실질 소유 주식 수는 108,618 보통�가 되었습니�.

RSU� � 차례� 걸쳐 베스팅됩니다: 2028� 8� 5일에 6,667�, 2029� 8� 5일에 6,667�, 2030� 8� 5일에 6,666주입니다. 판매, 옵션 행사 또는 기타 처분은 보고되지 않았습니�.

  • 이번 부여는 이사� 이익� 장기 주주 가치와 일치시키� 위한 비현� 주식 인센티브입니�.
  • 주식 희석은 점진적으� 2028년부� 2030년까지 분산되며, 계속 근무 � 베스� 조건� 따라 달라집니�.

Points clés du formulaire 4 : Journey Medical Corp. (DERM) a annoncé que la directrice Jayne Miranda Toledano a reçu 20 000 unités d'actions restreintes (RSU) le 05 août 2025 sans coût dans le cadre du Plan d'actions 2015. Cette attribution porte sa détention totale à 108 618 actions ordinaires.

Les RSU sont acquises en trois tranches : 6 667 actions le 05 août 2028, 6 667 le 05 août 2029 et 6 666 le 05 août 2030. Aucune vente, exercice d'option ou autre disposition n'a été signalée.

  • L'attribution constitue une incitation en actions non monétaire visant à aligner les intérêts de la directrice avec la création de valeur à long terme pour les actionnaires.
  • Toute dilution des actions sera progressive et répartie sur la période 2028-2030, sous réserve de la poursuite du service et des conditions d'acquisition.

Formular 4 Highlights: Journey Medical Corp. (DERM) meldete, dass Direktorin Jayne Miranda Toledano am 05.08.2025 20.000 Restricted Stock Units (RSUs) ohne Kosten im Rahmen des Aktienplans 2015 erhalten hat. Die Zuteilung erhöht ihren Gesamtbesitz auf 108.618 Stammaktien.

Die RSUs werden in drei Tranchen freigegeben: 6.667 Aktien am 05.08.2028, 6.667 am 05.08.2029 und 6.666 am 05.08.2030. Keine Verkäufe, Ausübung von Optionen oder andere Verfügungen wurden gemeldet.

  • Die Zuteilung ist ein nicht monetärer Aktienanreiz, der darauf abzielt, die Interessen der Direktorin mit dem langfristigen Wert für die Aktionäre in Einklang zu bringen.
  • Jegliche Aktienverwässerung erfolgt schrittweise und verteilt sich über den Zeitraum 2028-2030, abhängig von fortgesetztem Dienst und Vesting-Bedingungen.
Positive
  • None.
Negative
  • None.

Insights

TL;DR Routine RSU grant; boosts insider alignment, limited immediate market impact.

The filing shows no insider selling—only a 20,000-share equity award that increases the director’s stake to 108,618 shares. Because the RSUs vest over five years, the cash‐flow effect is minimal and dilution is deferred. While positive for governance, the grant is not large enough to alter valuation or near-term float; therefore I view the event as neutral for the stock.

TL;DR Long-dated RSUs enhance board alignment—marginally positive signal.

Granting multi-year RSUs rather than cash strengthens retention and links compensation to future performance. The absence of sales reduces concerns about insider sentiment. The staggered vesting through 2030 promotes long-term oversight, a modest governance positive, but the small size limits strategic impact.

Punti salienti del Modulo 4: Journey Medical Corp. (DERM) ha comunicato che la direttrice Jayne Miranda Toledano ha ricevuto 20.000 unità di azioni vincolate (RSU) il 05-ago-2025 senza alcun costo, nell'ambito del Piano Azionario 2015. Questo premio porta la sua proprietà totale a 108.618 azioni ordinarie.

Le RSU maturano in tre tranche: 6.667 azioni il 05-ago-2028, 6.667 il 05-ago-2029 e 6.666 il 05-ago-2030. Non sono state segnalate vendite, esercizi di opzioni o altre disposizioni.

  • Il premio è un incentivo azionario non monetario volto ad allineare gli interessi della direttrice con il valore a lungo termine per gli azionisti.
  • Eventuali diluizioni azionarie saranno incrementali e distribuite nel periodo 2028-2030, soggette a condizioni di servizio continuativo e maturazione.

Aspectos destacados del Formulario 4: Journey Medical Corp. (DERM) informó que la directora Jayne Miranda Toledano recibió 20,000 unidades de acciones restringidas (RSU) el 05-ago-2025 sin costo alguno bajo el Plan de Acciones de 2015. Esta concesión eleva su propiedad total a 108,618 acciones comunes.

Las RSU se liberan en tres partes: 6,667 acciones el 05-ago-2028, 6,667 el 05-ago-2029 y 6,666 el 05-ago-2030. No se informaron ventas, ejercicios de opciones ni otras disposiciones.

  • La concesión es un incentivo de capital no monetario diseñado para alinear los intereses de la directora con el valor a largo plazo para los accionistas.
  • Cualquier dilución de acciones será incremental y se distribuirá durante el período 2028-2030, condicionada al servicio continuo y a las condiciones de adquisición.

Form 4 주요 내용: Journey Medical Corp. (DERM)은 이사 Jayne Miranda Toledano가 2015� 주식 계획� 따라 2025� 8� 5일에 무상으로 20,000 제한 주식 단위(RSU)� 받았다고 보고했습니다. � 수상으로 그녀� � 실질 소유 주식 수는 108,618 보통�가 되었습니�.

RSU� � 차례� 걸쳐 베스팅됩니다: 2028� 8� 5일에 6,667�, 2029� 8� 5일에 6,667�, 2030� 8� 5일에 6,666주입니다. 판매, 옵션 행사 또는 기타 처분은 보고되지 않았습니�.

  • 이번 부여는 이사� 이익� 장기 주주 가치와 일치시키� 위한 비현� 주식 인센티브입니�.
  • 주식 희석은 점진적으� 2028년부� 2030년까지 분산되며, 계속 근무 � 베스� 조건� 따라 달라집니�.

Points clés du formulaire 4 : Journey Medical Corp. (DERM) a annoncé que la directrice Jayne Miranda Toledano a reçu 20 000 unités d'actions restreintes (RSU) le 05 août 2025 sans coût dans le cadre du Plan d'actions 2015. Cette attribution porte sa détention totale à 108 618 actions ordinaires.

Les RSU sont acquises en trois tranches : 6 667 actions le 05 août 2028, 6 667 le 05 août 2029 et 6 666 le 05 août 2030. Aucune vente, exercice d'option ou autre disposition n'a été signalée.

  • L'attribution constitue une incitation en actions non monétaire visant à aligner les intérêts de la directrice avec la création de valeur à long terme pour les actionnaires.
  • Toute dilution des actions sera progressive et répartie sur la période 2028-2030, sous réserve de la poursuite du service et des conditions d'acquisition.

Formular 4 Highlights: Journey Medical Corp. (DERM) meldete, dass Direktorin Jayne Miranda Toledano am 05.08.2025 20.000 Restricted Stock Units (RSUs) ohne Kosten im Rahmen des Aktienplans 2015 erhalten hat. Die Zuteilung erhöht ihren Gesamtbesitz auf 108.618 Stammaktien.

Die RSUs werden in drei Tranchen freigegeben: 6.667 Aktien am 05.08.2028, 6.667 am 05.08.2029 und 6.666 am 05.08.2030. Keine Verkäufe, Ausübung von Optionen oder andere Verfügungen wurden gemeldet.

  • Die Zuteilung ist ein nicht monetärer Aktienanreiz, der darauf abzielt, die Interessen der Direktorin mit dem langfristigen Wert für die Aktionäre in Einklang zu bringen.
  • Jegliche Aktienverwässerung erfolgt schrittweise und verteilt sich über den Zeitraum 2028-2030, abhängig von fortgesetztem Dienst und Vesting-Bedingungen.
2025falseFY000189988300018998832025-08-072025-08-07

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): August 7, 2025
FTAI INFRASTRUCTURE INC.
(Exact name of registrant as specified in its charter)
Delaware
001-41370
87-4407005
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification Number)
1345 Avenue of the Americas, 45th Floor
New York, New York 10105
(Address of principal executive offices and zip code)
(212) 798-6100
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, par value $0.01 per shareFIPThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company    
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.02. Results of Operations and Financial Condition.
On August 7, 2025, FTAI Infrastructure Inc. (“FIP” or the “Company”) issued a press release announcing the Company’s results for its fiscal quarter ended June 30, 2025. A copy of the Company’s press release is attached to this Current Report on Form 8-K (the “Current Report”) as Exhibit 99.1 and is incorporated herein solely for purposes of this Item 2.02 disclosure.
This Current Report, including the exhibit attached hereto, is being furnished and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth as being incorporated by reference into such filing.

Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.

Exhibit NumberDescription
99.1
Press release, dated August 7, 2025, issued by FTAI Infrastructure Inc.
104
Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Dated: August 7, 2025

FTAI INFRASTRUCTURE INC.
/s/ Kenneth J. Nicholson
Kenneth J. Nicholson
Chief Executive Officer and President

FTAI INFRASTRUCTURE INC

NASDAQ:FIP

FIP Rankings

FIP Latest News

FIP Latest SEC Filings

FIP Stock Data

823.99M
106.79M
6.95%
93.77%
10.7%
Conglomerates
Railroads, Line-haul Operating
United States
NEW YORK